))
Assessing Novel Approaches to Glycaemic Control in Type 2 Diabetes
Archived series ("Inactive feed" status)
When?
This feed was archived on July 07, 2017 14:54 (
Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 121536546 series 108502
Content provided by NUVIS Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by NUVIS Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this educational activity, Dr. Michael Nauck first describes the long-term pathophysiological defects associated with type 2 diabetes progression, and how theses defects help explain the need for therapies that can achieve glucose homeostasis through novel mechanisms of action. He then takes a closer look at some of these mechanisms of action, in particular those using the incretin hormones and glucose metabolism. In the second presentation, Dr. Juliana Chan examines the efficacy and safety data of three novel, available and emerging treatment strategies (DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors), as well as their potential impact on glycaemic control. Dr. Chan will then review where the approved therapies fit into treatment regimens, with a specific emphasis on international treatment guidelines.
…
continue reading
4 episodes
Share
